Verve Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 200.07 million compared to USD 157.39 million a year ago. Basic loss per share from continuing operations was USD 3.12 compared to USD 2.91 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.16 USD | -0.96% | -7.23% | -55.81% |
Apr. 03 | Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating | MT |
Apr. 02 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.81% | 517M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VERV Stock
- News Verve Therapeutics, Inc.
- Verve Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023